FOR IMMEDIATE RELEASE:
(of interest to editors covering:
Medical, Biotech, Pharma, Business-Patents)
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer
Medicine: Company Expands Impressive Intellectual Property Estate
SAN MARINO, Calif., Dec. 16, 2008 (SEND2PRESS NEWSWIRE) -- Epeius
Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems,
has received two additional European patents for the platform targeting
technologies and molecular designs that enable precision gene delivery to
primary cancers and metastatic lesions that have spread throughout the body.
With profound demonstrations of clinical benefit and single-agent-efficacy, as
well as overall safety, Epeius Biotech continues to lead the field of clinical
gene medicine with the advent of pathotropic (or disease-seeking) targeting.
These latest EU patents follow on the heels of a major clinical patent that
was recently awarded in the USA for targeted gene delivery in vivo.
Together these clinical patents provide additional intellectual property
protection for the platform of highly advanced biotechnologies embodied in the
company's leading anti-cancer agent Rexin-G(R)-the first and so far only
tumor-targeted gene delivery system that has been successfully validated in
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new
generation of powerful biological anti-cancer agents that are exceedingly
precise and highly selective for diseased tissues is currently in clinical
development. Anti-cancer agents such as Rexin-G(R) can be delivered by simple
intravenous infusion, yet are programmed to seek-out and accumulate
selectively in primary and metastatic lesions that have spread throughout the
body, delivering a tumor-killing gene while sparing normal cells and tissues.
Representing the world's first targeted genetic medicine proven to be both
safe and effective in the clinic, Rexin-G(R) is commercially available in the
Philippines-for use in all solid tumors that are refractory to stand